Postoperative Chemoradiotherapy With S-1 in Gastric Cancer

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was conducted to evaluate the clinical outcomes and toxicities of adjuvant treatment including S-1/cisplatin chemotherapy followed by S-1 based CRT.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chonnam National University Hospital
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• Age > 18 years

• Histologically proven gastric adenocarcinoma which is complete resected

• ECOG performance status of 1 or lower

• Adequate bone marrow function

• absolute neutrophil count [ANC] ≥1,500µL, and platelets ≥100,000/µL

• Adequate kidney function (serum creatinine < 1.5 mg/dL)

• Adequate liver function (serum total bilirubin < 2 times the upper normal limit (UNL) serum transaminases levels <2 times UNL

• No prior chemotherapy

Exclusion Criteria:

• Other tumor type than adenocarcinoma

• Evidence of distant metastasis

• Past or concurrent history of neoplasm except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri

• Uncontrolled infection

• Unstable cardiac disease despite treatment, myocardial infarction within months prior to study entry

• History of significant neurologic or psychiatric disorders including dementia or seizures

• Other serious underlying medical conditions which could impair the ability of the patient to participate in the study

• Symptoms of gastrointestinal obstruction

• concomitant drug medication: The following drugs cause drug interaction with S-1.